Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Is It Time To Sell Vaccine Stocks?

By Investing.com (Haris Anwar/Investing.com)Stock MarketsNov 05, 2021 09:14
ng.investing.com/analysis/is-it-time-to-sell-vaccine-stocks-96289
Is It Time To Sell Vaccine Stocks?
By Investing.com (Haris Anwar/Investing.com)   |  Nov 05, 2021 09:14
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

A powerful rally in the shares of companies that produced breakthrough vaccines to provide protection against the deadly coronavirus is showing signs of peaking.

Moderna (NASDAQ:MRNA) shares closed down almost 18% yesterday after the company’s sales and earnings missed analysts’ target by a big margin. The Massachusetts-based Moderna told investors its vaccine sales would be between $15 billion and $18 billion in 2021. Previously, the company had said it had signed agreements for $20 billion in anticipated 2021 vaccine sales.

In a statement, Moderna said longer lead times for international orders may shift some deliveries into 2022. The company cited a “temporary impact” as it attempts to expand its capacity to fill and finish vaccine vials.

Moderna stock, which closed yesterday at $284.02, has lost a quarter of its value during the past three months and more than 40% since reaching a record high in August. Pfizer (NYSE:PFE), another global vaccine giant, has hardly budged during the past three months.

Pfizer Weekly Chart.
Pfizer Weekly Chart.

Even before Moderna’s earnings setback, investors in vaccine stocks were getting nervous on the long-term viability of this trade. Vaccine stocks got hammered last month after the drug-maker Merck & Company (NYSE:MRK) said a study showed its pill slashed the risk of getting seriously ill or dying from COVID.

Merck Weekly Chart.
Merck Weekly Chart.

Twenty months into the pandemic, a successful rollout of a COVID-19 pill could quicken and broaden the world’s recovery, diminishing the appeal for vaccine stocks.

The U.K. became the first country to authorize Merck’s take-home therapy yesterday.

U.K. Health Secretary Sajid Javid said in a statement:

“This will be a game-changer for the most vulnerable and the immunosuppressed, who will soon be able to receive the groundbreaking treatment.”

Vaccines Versus Therapies

Besides the Merck pill, there are other competitors and potential therapies emerging that could hit sales of the leading vaccine producers, including Moderna, Pfizer and Johnson & Johnson (NYSE:JNJ). A generic and low-cost anti-depressant, for example, may reduce the risk that COVID-19 will land an infected patient in the hospital, according to a Brazilian study published in the Lancet Global Health journal.

In the largest clinical trial evaluating the anti-depressant’s effect on COVID-19 to date, patients who received fluvoxamine were significantly less likely to require hospitalization than those who didn’t, according to a Wall Street Journal report.

India, one of the largest vaccine producers, is quickly expanding its exports after its earlier setbacks due to increased demand at home. The World Health Organization this week granted emergency authorization to a COVID vaccine co-developed by India’s medical-research agency and local manufacturer Bharat Biotech International Ltd. The WHO’s approval may accelerate the resumption of vaccine shipments from India, which halted exports in April to prioritize its own citizens amid a lethal second coronavirus wave.

According to Morgan Stanley analyst Matthew Harrison, vaccines continue to remain the primary prevention measure and largest market opportunity, but it’s unclear how big that market will be.

Harrison’s forecast for annual coronavirus vaccine sales over the long term ranges from $3 billion to $30 billion. He has equal-weight ratings on Pfizer and Moderna.

Bottom Line

We believe the best days to make money on vaccine stocks are behind us. More vaccine supplies, from the low-cost producers like India to the authorization of antiviral pills like the one Merck has developed, will continue to weigh on the sales of western vaccine producers, including Moderna and Pfizer.

Is It Time To Sell Vaccine Stocks?
 

Related Articles

Is It Time To Sell Vaccine Stocks?

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email